Wyeth closing Penn. facility
Executive Summary
Wyeth will be closing its West Chester, Penn. manufacturing facility effective December 2004. Wyeth ceased manufacturing its own products at the facility in fall 2004 and has been operating as a third party manufacturer to King and Baxter ever since. The facility was manufacturing bicillin and penicillin injectables for King and ampicillin and sulbactam for Baxter...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.